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Mixed cryoglobulinemia (MC) is an autoimmune/B-cell lymphoproliferative disorder associated with Hepatitis C Virus (HCV)
infection, manifesting as a systemic vasculitis. In the last decade, antiviral treatment (AT) with pegylated interferon (Peg-IFN)
plus ribavirin (RBV) was considered the first therapeutic option for HCV-MC. In MC patients ineligible or not responsive to
antivirals, the anti-CD20 monoclonal antibody rituximab (RTX) is effective. A combined AT plus RTX was also suggested. Since
the introduction of direct acting antivirals (DAAs), few data were published about MC and no data about a combined schedule.
Here, we report a complete remission ofMC after a sustained virological response following a combined RTX/Peg-IFN+RBV+DAA
(boceprevir) treatment and review the literature about the combined RTX/AT.
1. Introduction
Mixed cryoglobulinemia (MC) is both an autoimmune and
B-cell lymphoproliferative disorder (LPD) characterized by
immune complexes (cryoglobulins, CGs) that reversibly pre-
cipitate at low temperature [1].
In the largemajority of cases,MC is triggered byHepatitis
C Virus (HCV) infection.
HCV is both a hepatotropic and lymphotropic virus and
may lead not only to liver diseases, but also to some lym-
phoproliferative disorders ranging from the benign MC to
malignant B-cell non-Hodgkin’s lymphoma [2].
Small-to-medium sized vessel vasculitis is the pathologi-
cal substrate of the MC-related clinical syndrome (MCS) [1].
Antiviral therapy (AT) has been indicated as first-line
therapy in patients with mild-to-moderate HCV-related
MCS. The use of IFN-𝛼 to treat MC was successfully pro-
posed, even before HCV discovery, because of its antipro-
liferative and immunomodulatory effects [3]. However,
the benefit was transient and relapses were very frequent
after treatment discontinuation when viral eradication was
not achieved [4–6].
Starting with the IFN monotherapy, the efficacy of AT
progressively increased during two decades thanks to the use
of Peg-IFN and RBV. The increased antiviral activity was
associated with an increased clinical effectiveness in patients
with MCS [2, 7, 8].
In severe cases and/or in patients intolerant or ineligible
to AT, the usefulness and safety of anti-CD20 monoclonal
antibody rituximab (RTX) have been clearly shown in several
studies. RTX was shown to be highly effective in modifying
the dynamics of B cells by deleting expanded clones and
markedly improving MCS in most cases [9–11].
Peg-IFN plus RBV has been considered the standard AT
for about a decade [12]. Recently, the direct acting antiviral
drugs (DAAs), inhibitor of the nonstructural 3/4AHCV pro-
tease, boceprevir (BOC), and telaprevir, in combination with
Peg-IFN and RBV, have consistently increased the likelihood
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Table 1: Main clinical and laboratory data before rituximab (RTX-
baseline), 2 months after rituximab cycle (BOC-baseline), and at

















Stiffness (kPa) 14.5 12 11.7
HCV titer (IU × 106/mL) 0.98 1.39 NEG
ALT (IU/L)† 44 37 19
MC manifestations
Clinical
Purpura ++ − −
Arthralgia ++ + −
Weakness ++ − −
Peripheral neuropathy − − −
Raynaud syndrome − − −
Nephritis − − −
Sicca syndrome ++ + +
Laboratory
Cryocrit (%) 5 0 0
RF (IU/mL)§ 24 <10 <10
C4 (mg/dL)‡ 9 16 25
RTX: rituximab; BOC: boceprevir; MC: mixed cryoglobulinemia; IL28B:
polymorphism of interleukin-28B; stiffness: liver stiffness as evaluated
by transient elastography; kPa: kilopascal; IU: international units; ALT:
alanine aminotransferase; RF: rheumatoid factor. †Normal values: <40 IU/L;
§normal values: <10 IU/mL; ‡normal values: from 10 to 40mg/dL.
of response in patients infected with HCV genotype 1 (Gt 1a
or 1b) [13, 14]. Few data are still available for patients with
HCV-related MCS treated with DAAs [15–18] and no clear
information exists about the combination with RTX.
Here we describe, for the first time, a case of HCV-
related MCS treated with the combination of RTX and BOC-
based triple AT and review the available literature about the
combination of RTX and anti-HCV therapy.
2. Case Report
In May, 2010, a 63-year-old woman with a 30-year history of
HCV (Gt 1b) chronic infection and harboring compensated
liver cirrhosis with normal liver function tests and no
signs of portal hypertension was evaluated at the MASVE
Center of the University of Florence. The main clinical and
laboratory data are detailed in Table 1.The analysis of cryocrit
was performed in the MASVE laboratory at every medical
appointment. Briefly, the patient blood was kept at 37∘–40∘C
to avoid CGs precipitation; immediately after centrifugation,
a special graduated glass tube (Wintrobe tube) has been filled
with 1.0mL of serum, placed at 4∘C, and examined after at
least 7 days to assess the percentage of packed cryoglobulins.
The reduction of C4 complement component and the RF
levels was performed as routine tests by the CentralizedDiag-
nostic Laboratory of the Careggi Hospital, Florence, Italy, by
immunoturbidimetric method and immunoenzymatic assay,
respectively.
Since 2008, the patient showed a typical MCS [19] char-
acterized by recurrent lower limb purpura, arthralgia/
arthritis of hands and shoulders, and burning paresthesia
with “bootie” distribution. She repeatedly scored positive for
mixed type II (polyclonal IgG/monoclonal IgMk) cryoglob-
ulins as well as rheumatoid factor (RF), increased inflamma-
tory markers, and low C4. The patient previously failed two
Peg-IFN𝛼-2b+RBV treatments. Her interleukin-28b (IL28b)
genotype (rs12979860) was T/T, a negative predictor of
response to IFN-based therapy [20]. In June 2010, the patient
underwent treatment with RTX (1 g twicemonthly) which led
to a complete MCS clinical response, with improvement in
all baseline clinical manifestations [21]. After recurrence of
symptoms in July 2011, the treatment was repeated. Clinical
conditions consistently improved and in September 2011 the
patient underwent AT.TheBOC-based treatment was chosen
on the basis of negative predictors of response [12] and higher
efficacy of triple therapy compared to dual one.
After a 4-week lead-in phase with Peg-IFN𝛼-2b (1.5 𝜇g/
Kg/week, subcutaneously) plus RBV (800mg/daily, orally),
BOC was added (800mg three times daily, orally) and triple
therapy was continued for 44 weeks.
Viremia disappeared 1 week after BOC administration
and remained negative throughout therapy and follow-up
(sustained virological response).
The cryocrit scored negative during therapy and follow-
up and C4 and RF remained persistently normal (Table 1 and
Figure 1).
During treatment, the patient did not experience purpura
or arthritis. She developed anemia and neutropenia requir-
ing administration of erythropoietin and granulokines and
reduction of RBV (600mg/daily).
After therapy, the patient was regularly checked up every
three months. During every scheduled check-up C4, RF,
cryocrit levels as well as liver functional parameters, and
viremia were evaluated (data not shown).
We observed long-term clinical and virological response:
after a 15-month follow-up, the patient no longer had pur-
pura, arthritis, or other baseline symptoms. Persistence of
mild xerostomia and xerophthalmia was occasionally treated
with symptomatic drugs (Table 1).
3. Review of the Literature
We performed a literature search on PubMed about com-
bined/sequential treatment of MC (Table 2).
In the first pilot study, Saadoun et al. treated 16 con-
secutive, unselected refractory HCV-MC patients with RTX
followed by ATwith Peg-IFN and RBV. 15/16 patients showed
clinical improvement, with a good profile of safety [22].


















































































































Figure 1: (a) Viral kinetics: a slight decrease in serumHCVRNA values was observed during the lead-in phase. Soon after the introduction of
boceprevir (week 4), a drastic reduction in viremia was observed, with complete negativization at week 5. The vertical dashed line represents
the introduction of boceprevir; the horizontal continuous line indicates the detection limit of theHCVRNA test (15 IU/mL). IU: international
units; mL: milliliter; w: week; f. up: follow up; m: month. (B) Cryocrit C4 and RF kinetics during the combined therapy (RTX+Peg-
IFN+RBV+BOC). The time points considered are (1) before rituximab (June 2011), (2) two months after rituximab cycle (September 2011;
triple therapy baseline), and (3) end of the follow-up after boceprevir-based antiviral therapy (November 2013). After RTX therapy cryocrit,
C4 and RF normalized and remained persistently normal. (e) Cryocrit; (◼) rheumatoid factor; (󳵳) C4. RF: rheumatoid factor; normal values:
<10 IU/mL; normal values of C4: from 10 to 40mg/dL.
Table 2: Combined treatment with antiviral therapy and rituximab in MC patients: review of the literature.






2008 [22] 16 Refractory MC
ST
(RTX 375mg/sqm × 4
Peg IFN𝛼2b+ + RBV++ after a month)
(10/6/1) 2∘
Terrier et al., 2009
[23] 20 Severe MC
ST
(RTX 375mg/sqm × 4 or 1 gr × 2







(RTX 375mg/sqm × 4 weekly + two 5
monthly inf. + Peg IFN𝛼2b+ or 𝛼2a+++ +
RBV++)
(12/5/5) 3∘∘∘





(RTX 375mg/sqm × 4 or 1 gr × 2
Peg IFN𝛼2b+ or 𝛼2a+++ + RBV++ after a
month)
(28/9/1) 5∘∘+
Ignatova et al., 2014
[26] 6 Severe MC
ST
(RTX n.d. dose
Peg IFN𝛼 + RBV++ after a month)
(n.d./n.d./n.d.) n.d.
MC: mixed cryoglobulinemia; ST: sequential treatment; CT: combined treatment; CR: complete response, PR: partial response, NR: no response; AEs: adverse
events (requiring antiviral treatment interruption); n.d.: not determined.
+1.5mcg/kg weekly; ++weight-based; +++180mcg weekly.
∘One worsening of peripheral neuropathy case and 1 flare of psoriasis case.
∘∘Two hematologic toxicity cases; 1 flare of psoriasis case; 1 hepatocarcinoma case.
∘∘∘One severe anemia case; 2 grade 4 neutropenia cases.
∘∘+Two hematologic toxicity cases; 1 depression case; 1 flare of psoriasis cases; 1 neuropathy case.
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A subsequent study of Terrier et al. comprised 32 severe
HCV-MCS patients, treated either with RTX monotherapy
(12 patients) or with RTX followed by AT (20 patients, 11
already included in the previous pilot study). The authors
reported the efficacy of RTX, with a better response in
RTX/Peg-IFN+RBV group [23].
In 2010 Dammacco et al. and Saadoun et al. published
two studies on the use of RTX and AT with Peg-IFN+RBV
according to a combined [24] or sequential [25] scheme.
In the first study, 37 HCV-MCS patients, näıve for IFNs
or previous administration of immunosuppressive drugs,
were randomized to get a RTX/Peg-IFN+RBV treatment
(22 patients) or Peg-IFN+RBV (15 patients, controls) [24].
Patients in the first group obtained a significantly higher
rate of complete and sustained response, without increase of
adverse events.
In the second study, a prospective, nonrandomised cohort
study of 93 patients, Saadoun et al. found that combined
therapy reduced the clinical remission time, improved renal
response rate, and led to higher rates of cryoglobulin
clearance and clonal VH1-69+B cell suppression than Peg-
IFN+RBV alone [25].
In a recent letter, Ignatova and coworkers described
18 patients who underwent AT with Peg-IFN+RBV. In six
subjects, RTX was administered 1 month before AT in
order to treat severe MC. Data of this report confirm that
AT increases the relapse-free survival compared with stan-
dard immunosuppression or RTX alone and that combined
RTX/AT schedule can be useful in moderate/severe MC [26,
27].
4. Discussion
Patients’ response to AT has been shown to be lower in
HCV patients with MC than without, after both double
(Peg-IFN+RBV) and BOC-based triple therapy [15, 28].
The reasons for a lower propensity to eradicate HCV are
unknownbut are possibly related to a stronger involvement of
lymphatic cells (especially B-cell) by the infection in MC [1]
leading to more consistent viral reservoirs and, when using
DAAs, a higher risk of viral mutations.
The usefulness and safety of RTX in MC have been
clearly shown in numerous studies, including also patients
with advanced liver disease [11, 21, 29–31], even if most
patients treatedwithRTX-monotherapy experienced vasculi-
tis relapse following B-cell recovery [23].
Combined therapywith RTXplus Peg-IFN+RBV, accord-
ing to a sequential or contemporary scheme, has previously
provided an improvement of clinical response and higher
cryoglobulin clearance than Peg-IFN+RBV, in the absence
of increasing adverse events [23–25, 32]. The pathogenetic
bases could be linked to the association of cooperating
mechanisms, like the viral eradication and the depletion
of the pathological B-cell clones. Furthermore, the B-cell
depletion could favor the elimination of a viral reservoir. On
the other hand, the clinical improvement obtained with RTX
treatment could make eligible to AT patients previously not
eligible.
Interestingly, in our previous study on 35 HCV chroni-
cally infected subjects, the onlyMCS patient who persistently
responded to treatment was the one excluded from the
comparative analysis owing to a recent treatment with RTX
[15].
In the same study we showed a sudden decrease in cry-
ocrit together with the rapid decrease of viremia due to the
introduction of BOC, stressing the role exerted by viral rep-
lication in MC pathogenesis [15].
In conclusion, we are reporting here the first description
of a safe and highly efficacious combination of RTX and
BOC-based AT in a patient with cryoglobulinemic vasculitis.
The persistent response was both virological and clinical. Our
previous observation of a low rate of virological response
in MCS patients may increase the interest of this report
which seems to agree with the hypothesis of a key role played
by B cells as HCV reservoirs. Such an observation appears
to confirm the positive effect of a combined therapeutic
approach also when using DAA-dependent AT.
These results were, however, obtained in a single case and
further studies based on significant numbers of patients are
needed in order to confirm our observations in the specific
setting of patients with HCV-related MC.
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